Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate The Safety and Tolerability of CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies.

NCT03795779 is registered in ClinicalTrials.gov with iCell Gene Therapeutics as lead sponsor.

NCT NCT03795779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03795779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate The Safety and Tolerability of CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies.
Lead sponsor
iCell Gene Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2018
Completion date
September 30, 2022
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myeloid leukemia, hematologic malignancy, myelodysplastic syndromes, myeloproliferative neoplasm